Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence

Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence To the Editor: In their study of patients with electrocardiographic left ventricular hypertrophy (LVH), Dr Okin and colleagues1 identify an association between LVH regression as measured by the Cornell product and decreased risk of atrial fibrillation. They cite a prior study2 of this simple and low-cost electrocardiographic measure that shows a correlation with LVH. It would be helpful to know if the authors have any information indicating whether the correlation of the Cornell measure remains intact during a treatment maneuver compared with a test such as echocardiography that was not performed in their present study. In addition, because patients often ask about the time frame after initiating hypertensive treatment in which they can expect a regression of their newly diagnosed LVH, it would be useful if the authors could provide data on the mean or median time to LVH regression after initiation of the protocol. Back to top Article Information Financial Disclosures: None reported. References 1. Okin PM, Wachtell K, Devereux RB. et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296:1242-124816968848Google ScholarCrossref 2. Okin PM, Roman MJ, Devereux RB. et al. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-4237829796Google ScholarCrossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence

JAMA , Volume 297 (1) – Jan 3, 2007

Loading next page...
 
/lp/american-medical-association/left-ventricular-hypertrophy-regression-and-atrial-fibrillation-6aqSZPNQUK
Publisher
American Medical Association
Copyright
Copyright © 2007 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.297.1.40-a
Publisher site
See Article on Publisher Site

Abstract

To the Editor: In their study of patients with electrocardiographic left ventricular hypertrophy (LVH), Dr Okin and colleagues1 identify an association between LVH regression as measured by the Cornell product and decreased risk of atrial fibrillation. They cite a prior study2 of this simple and low-cost electrocardiographic measure that shows a correlation with LVH. It would be helpful to know if the authors have any information indicating whether the correlation of the Cornell measure remains intact during a treatment maneuver compared with a test such as echocardiography that was not performed in their present study. In addition, because patients often ask about the time frame after initiating hypertensive treatment in which they can expect a regression of their newly diagnosed LVH, it would be useful if the authors could provide data on the mean or median time to LVH regression after initiation of the protocol. Back to top Article Information Financial Disclosures: None reported. References 1. Okin PM, Wachtell K, Devereux RB. et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296:1242-124816968848Google ScholarCrossref 2. Okin PM, Roman MJ, Devereux RB. et al. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-4237829796Google ScholarCrossref

Journal

JAMAAmerican Medical Association

Published: Jan 3, 2007

References